Vulvovaginal Candidiasis Treatment Market to Grow with a CAGR of 4.52% through 2030
Increasing
prevalence of chronic diseases is expected to drive the growth of global
vulvovaginal candidiasis treatment in the forecast period, 2026-2030.
According to TechSci Research report, “Vulvovaginal Candidiasis
Treatment Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2030F”, the Global Vulvovaginal Candidiasis Treatment Market
Market stood at USD 987.23 million in 2024 and is anticipated to grow with a
CAGR of 4.52% in the forecast period through 2030. This can be ascribed to
the increasing prevalence of diabetes cases and increasing unrestrained usage
of antibiotics leading to high prevalence of yeast infection among individuals
across the globe. Additionally, increasing demand for better treatment and the
rising burden of different chronic diseases like neurological disorder, and
cancer, especially in the developed countries in the North America and Europe,
are expected to create lucrative opportunities for market growth in the coming
years. Besides, increasing research and development activities in healthcare
industry is further expected to support the market growth. Similarly, growing
approval of newly developed antifungal drugs and increasing the number of
market players are expected to boost market growth during the forecast period.
Also, growing awareness about new drugs for the treatment of fungal diseases
and growing demand for advanced therapeutic options will drive the market
growth over the years.
However,
increasing resistance for antifungal drugs among the population is slowing down
the growth of global vulvovaginal candidiasis treatment market in the forecast
period. Similarly, high risks and complications associated with drugs such as
the incidence of miscarriage due to fluconazole and treatments may hamper the
vulvovaginal candidiasis treatment market growth during the forecast period.
Also, the lack of awareness about maintaining good hygiene among the female
population, in emerging countries, can further restrict the growth of the
global vulvovaginal candidiasis treatment market.
The
Global Vulvovaginal Candidiasis Treatment Market is segmented into drug class, route of
administration, distribution channel, regional distribution and company.
Based on Route of Administration, the Topical is witnessing
the fastest growth globally. This accelerated growth is driven by several
patient-centered and clinical factors that make topical therapies increasingly
preferred, especially for localized infections like VVC. Topical antifungal
treatments, which include creams, ointments, vaginal suppositories, and ovules,
provide direct application of the medication to the affected site, enabling
rapid relief of symptoms such as itching, irritation, and discharge. This
localized approach helps to minimize systemic exposure and reduces the risk of
systemic side effects, which can be a concern with oral or intravenous
therapies. One significant factor contributing to the rising preference for
topical treatments is the increasing incidence of fluconazole-resistant Candida
species. Resistance to oral azoles, particularly fluconazole, has necessitated
alternative treatment approaches. Topical therapies often use antifungal agents
such as clotrimazole, miconazole, terconazole, and nystatin, which remain
effective against many resistant strains. Additionally, newer topical
formulations with enhanced bioavailability and improved patient adherence are
being introduced to the market.
Based on the Region, The Asia-Pacific region is projected to
witness the fastest growth in the global vulvovaginal candidiasis (VVC)
treatment market due to rising awareness of women’s health, increasing
urbanization, greater access to healthcare services, and a large population
base. Countries such as China, India, Japan, and South Korea are at the
forefront of this surge, driven by both public health initiatives and changing
demographic and lifestyle patterns that contribute to the rising incidence of
VVC. According to the World Health Organization (WHO) Southeast Asia Regional
Office, reproductive tract infections—including vulvovaginal candidiasis—affect
millions of women across the region. A WHO study on reproductive health in
India highlighted that up to 20% of women attending gynecological clinics
reported symptoms consistent with vaginal infections, including candidiasis.
Similar patterns have been reported in rural and urban communities in
Bangladesh, Indonesia, and Nepal.
Major
companies operating in Global Vulvovaginal Candidiasis Treatment Market are:
- Astellas
Pharma Inc.
- Mycovia
Pharmaceuticals, Inc.
- Basilea
Pharmaceutica Ltd.
- Scynexis,
Inc.
- Grupo
Ferrer Internacional, S.A.
- Pfizer,
Inc.
- Pacgen
Life Science Corporation
- NovaDigm
Therapeutics, Inc.
- Cidara
Therapeutics, Inc.
- Amplyx
Pharmaceuticals Inc.
Customers can also request for 10% free customization on this report.
“Technological advancements have also played a part, as digital health platforms now allow patients to self-assess symptoms and purchase antifungal treatments online. Telehealth services enable pharmacists and clinicians to advise patients remotely, encouraging a shift toward home-based, convenient treatment. This trend has especially surged post-COVID-19, with patients preferring to avoid clinical visits unless necessary. Additionally, the inclusion of VVC treatments in national essential medicines lists—as seen in India’s National List of Essential Medicines (NLEM)—ensures that common antifungal agents are widely available and affordable, supporting self-treatment options in both urban and rural areas”, said Mr. Karan Chechi, Research Director of TechSci Research, a
research based global management consulting firm.
“Vulvovaginal Candidiasis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Drug Class (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others), By Route of Administration (Oral, Intravenous, Topical), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region and Competition, 2020-2030F”, has evaluated the future growth potential
of global vulvovaginal candidiasis treatment market and provides statistics
& information on market size, structure, and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in global vulvovaginal candidiasis treatment market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com